For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| General and administrative expenses | 17,920,391 | |||
| Research and development expense | 7,721,436 | |||
| Research and development expense (excluding acquired in process cost) | 8,717,475 | |||
| Operating expenses | 34,359,302 | |||
| Loss from operations | -34,359,302 | |||
| Finance income | -197,382 | |||
| Represents the amount of gain loss on settlements | -278,854 | |||
| Represents the amount if change in fair value of debentures | -583,823 | |||
| Repayment of debentures on extinguishment | -25,000 | |||
| Total other income | -1,085,059 | |||
| Net loss for the year | -35,444,361 | |||
| Deemed dividend on warrant inducement | 11,837,298 | |||
| Net income (loss) available to common stockholders, basic | -47,281,659 | |||
| Foreign exchange gain/loss | -10,730 | |||
| Comprehensive income (loss), net of tax, attributable to parent | -47,292,389 | |||
| Basic EPS | -2.74 | |||
| Diluted EPS | -2.74 | |||
| Basic Average Shares | 17,283,824 | |||
| Diluted Average Shares | 17,283,824 | |||
Medicus Pharma Ltd. (MDCXW)
Medicus Pharma Ltd. (MDCXW)